Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

40.42 +1.02 (+2.59%)
Official Closing Price Updated: 7:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biohaven Ltd

< Previous 1 2 3 4 5 6 7 Next >
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
The healthcare stocks to buy deserve more respect from investors who seek top-level growth outside of the tech sector. 
Via InvestorPlace
HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday
Via Benzinga
BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Biohaven Stock Wednesday?
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. 
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated... 
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Based on good technical signals, BIOHAVEN LTD is potentially setting up for a breakout.
BIOHAVEN LTD (NYSE:BHVN) showing some interesting technicals. Here's why. 
Via Chartmill
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are constantly on the hunt for undervalued, under-followed, and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.